Benitec, Biomics to Collaborate on Expressed RNAi Rx for HBV | GenomeWeb

Benitec announced this week that it has agreed to collaborate with Chinese biopharmaceutical shop Biomics Biotechnologies on the development of an expressed RNAi-based treatment for chronic hepatitis B infection.

Benitec said the companies first intend to develop a "project plan for target identification and validation." Once a target has been selected, it will advance through preclinical and clinical testing.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.